Welcome to our dedicated page for AMRS news (Ticker: AMRS), a resource for investors and traders seeking the latest updates and insights on AMRS stock.
Amyris, Inc. (AMRS) is frequently featured in news coverage for its activities as a vertically integrated synthetic biology company focused on sustainable ingredients produced via precision fermentation. Company announcements highlight developments across its Lab-to-Market™ technology platform, industrial biomanufacturing assets, strategic partnerships, and financial and operational restructuring efforts.
News about Amyris often covers its strategic transformation initiatives, including programs aimed at cost reduction, portfolio simplification, and changes to its capital structure and liquidity. The company has publicly discussed a transformation program supported by external advisors, as well as the establishment of internal governance structures to oversee these efforts. A significant news event was the commencement of voluntary Chapter 11 proceedings by Amyris and certain domestic subsidiaries, described as a step to facilitate an operational and financial restructuring centered on its core sustainable ingredients business.
Investors and observers can also find updates on Amyris’ industrial biotechnology operations, such as its precision fermentation plant in Barra Bonita, Brazil. Recent news includes Amyris taking full ownership of this plant, investing in additional fermentation capacity, and winding down a joint venture while retaining manufacturing assets and royalty interests related to specific fermented ingredients.
Another recurring theme in Amyris news is the formation and evolution of strategic partnerships and licensing agreements. Press releases describe exclusive licenses for cosmetic ingredients, long-term manufacturing agreements, and collaborations for sustainable squalene and fermented sweetener technologies. Earnings updates and revenue guidance communications provide additional context on how these partnerships, ingredient sales, and technology access activities fit into the company’s broader strategic agenda.
This news page aggregates such company-issued releases and related coverage, offering a centralized view of key developments in Amyris’ synthetic biology, fermentation, partnership, and restructuring activities over time.
Amyris, Inc. (Nasdaq: AMRS) announced the successful start of fermentation at its new precision fermentation plant in Barra Bonita, Brazil, marking a significant milestone. This facility, featuring five mini-factories, allows the company to produce all 13 market molecules concurrently, responding to rising demand for sustainable ingredients in beauty, health, and wellness. The plant's capacity is fully committed through 2023, enabling efficient supply to customers. COO Eduardo Alvarez praised the team's achievement in completing this state-of-the-art facility during the pandemic.
Amyris, a synthetic biotechnology company listed on Nasdaq as AMRS, will engage in a virtual fireside chat at the Oppenheimer 22nd Annual Consumer Conference on June 14, 2022, at 11:15 am ET. This event highlights Amyris's commitment to sustainable consumption through its Lab-to-Market™ technology platform, which utilizes advanced machine learning and robotics to accelerate innovation in the Clean Health & Beauty and Flavors & Fragrances markets. A webcast will be available on their Investor Relations page.
Amyris, Inc. (Nasdaq: AMRS) announced participation in three investor conferences from May 23 to May 25, 2022. The events include the Morgan Stanley Sustainable Futures Conference, Cowen 6th Annual Future of the Consumer Conference, and UBS Global Healthcare Conference. These conferences will enhance Amyris's visibility in the sustainable consumption sector and showcase its Lab-to-Market™ technology platform, which leverages machine learning and robotics to innovate rapidly. Live webcasts of the presentations will be available on the company's Investor Relations website.
Amyris, Inc. (Nasdaq: AMRS) announced its participation in two upcoming investor conferences. The first is the Morgan Stanley Sustainable Futures Conference on May 23 at 2:00 PM ET (virtual), followed by the UBS Global Healthcare Conference on May 25 at 11:30 AM ET (in-person). Live webcasts of these presentations will be accessible through the company's Investor Relations section. Amyris leverages its Lab-to-Market technology platform to facilitate the transition to sustainable consumption.
Amyris, Inc. (Nasdaq: AMRS) reported Q1 2022 financial results, achieving a record consumer revenue of $34.6 million, a 121% increase from Q1 2021. Core revenue reached $57.7 million, up 75% year-over-year, despite total revenue declining 67% due to the absence of a one-off strategic transaction from the previous year. The company plans to launch new brands and expects consumer revenue to grow over 150% in 2022. Cash at the end of the quarter was $288 million, a substantial increase from $144 million a year prior.
Amyris, Inc. (Nasdaq: AMRS) will announce its financial results for Q1 2022 on May 10, 2022, before market opening. A conference call is scheduled for 6:00 a.m. PT (9:00 a.m. ET) where CEO John Melo and CFO Han Kieftenbeld will discuss the results and business updates. Amyris utilizes its Lab-to-Market™ platform to transition the Clean Health & Beauty and Flavors & Fragrances markets to sustainable ingredients, reaching over 300 million consumers with products in more than 20,000 brand offerings.
Amyris, a synthetic biotechnology leader, hosted a successful investor event on April 11, 2022, following its Nasdaq Opening Bell ceremony. Key highlights included presentations on its sustainable consumer brands powered by its Lab-to-Market™ technology platform and an update on its precision fermentation plant in Barra Bonita, Brazil, which recently began commissioning operations. The event also featured a consumer panel discussing trends in clean beauty and the benefits of Amyris' proprietary technology. CEO John Melo emphasized the company’s commitment to sustainable products and their increasing consumer appeal.
Amyris, Inc. (Nasdaq: AMRS) has begun commissioning its new fermentation plant in Barra Bonita, Brazil, a strategic investment poised to enhance its biotechnology manufacturing capabilities. The facility, located next to the Raizen sugar mill, will utilize sugar cane as a primary feedstock. The plant features a vertical fermentation process and five mini-factories for producing over 13 bio-fermented products. This development aims to address increasing consumer demand for bio-based products and strengthen Amyris's position in the biotechnology sector.
Amyris, Inc. (Nasdaq: AMRS), a leader in synthetic biotechnology, will participate in a fireside chat at the Jefferies Virtual Synthetic Biology Week on March 23, 2022, at 2:00 pm ET. This event aims to showcase Amyris's innovative Lab-to-Market™ technology, which accelerates the transition to sustainable consumption. Investors can access a live webcast and replay on the company’s Investor Relations page. Amyris is known for its sustainable ingredients used across over 20,000 products, impacting over 300 million consumers globally.
Amyris, Inc. (Nasdaq: AMRS) has completed the acquisition of MenoLabs, LLC, a company that focuses on women's health, particularly addressing menopause symptoms. MenoLabs offers research-backed, all-natural treatments, including its flagship product, MenoFit, and a subscription model for online sales. The acquisition supports Amyris's strategy in the wellness sector, leveraging MenoLabs' recurring revenue and innovative product line. With this move, Amyris aims to enhance its portfolio in sustainable health solutions, tapping into the growing demand for menopause-related products.